- Trials with a EudraCT protocol (55)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
55 result(s) found for: Contrast sensitivity function.
Displaying page 1 of 3.
EudraCT Number: 2022-000174-25 | Sponsor Protocol Number: 101090401IN | Start Date*: 2023-03-17 | |||||||||||
Sponsor Name:SANTEN INCORPORATED | |||||||||||||
Full Title: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehi... | |||||||||||||
Medical condition: Fuchs Endothelial Corneal Dystrophy (FECD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001874-32 | Sponsor Protocol Number: RDC-CNGA3-01 | Start Date*: 2015-09-09 | |||||||||||
Sponsor Name:Universitätsklinikum Tübingen | |||||||||||||
Full Title: Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observe... | |||||||||||||
Medical condition: CNGA3-linked achromatopsia | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022791-31 | Sponsor Protocol Number: D01092010AZNTG | Start Date*: Information not available in EudraCT | |||||||||||||||||||||||||||||||
Sponsor Name:University Erlangen-Nuremberg | |||||||||||||||||||||||||||||||||
Full Title: Contrast sensitivity of patients with normal tension glaucoma by application of Azarga® | |||||||||||||||||||||||||||||||||
Medical condition: The effect of AZARGA(R) on the central and spacial-temporal contrast sensitivity of patients with normal tension glaucoma will be examined. Healthy controls are required to prove the disease specif... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004142-35 | Sponsor Protocol Number: ABSALON | Start Date*: 2023-04-18 | |||||||||||
Sponsor Name:Department of Ophthalmology, Rigshospitalet | |||||||||||||
Full Title: Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON) | |||||||||||||
Medical condition: mild and moderate glaucoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002588-17 | Sponsor Protocol Number: SAM-IIT01 | Start Date*: 2019-10-21 |
Sponsor Name:Universitätsklinikum Tübingen | ||
Full Title: Safety and effects on visual function of 0.01% Atropin eye drops for myopia inhibition in children and adolescents | ||
Medical condition: Myopia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002873-80 | Sponsor Protocol Number: AMILCA-DIFLU | Start Date*: 2020-01-14 |
Sponsor Name:FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE | ||
Full Title: Unicentre, open, uncontrolled clinical trial to assess the morphological, biochemical and functional effects of Diflunisal treatment in patients with transthyretin cardiac amyloidosis | ||
Medical condition: transthyretin cardiac amyloidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004203-39 | Sponsor Protocol Number: FNKV-OFT-2013-1 | Start Date*: 2014-04-03 |
Sponsor Name:Fakultní nemocnice Královské Vinohrady | ||
Full Title: A randomized, 12 months, active controlled study of the efficacy of repeated doses of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy | ||
Medical condition: prolipherative diabetic retinopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004700-20 | Sponsor Protocol Number: 2104-02 | Start Date*: 2005-03-11 |
Sponsor Name:Epix Pharmaceuticals, Inc. | ||
Full Title: Phase II Feasibility study of safety and efficacy of Magnetic Resonance Imaging of Thrombi with EP-2104R in the detection in Venous Thromboembolism (VTE) | ||
Medical condition: Detection of venous thromboembolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000900-15 | Sponsor Protocol Number: B7A-MC-MBCU | Start Date*: 2005-08-19 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: The effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography | ||
Medical condition: Diabetic Macular Edema (DME), is the most common cause of visual impairment in patients with diabetic retinopathy (DR). It is the accumulation of extracellular fluid in the retinal tissues of the m... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DK (Completed) DE (Completed) ES (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004701-23 | Sponsor Protocol Number: 2104-03 | Start Date*: 2005-03-14 |
Sponsor Name:Epix Pharmaceuticals, Inc. | ||
Full Title: Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambers | ||
Medical condition: Detection of thrombi in the arterial vasculature and cardiac chambers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003705-34 | Sponsor Protocol Number: RDC-PDE6A-01 | Start Date*: 2019-07-02 |
Sponsor Name:Universitätsklinikum Tübingen | ||
Full Title: PIGMENT – PDE6A gene therapy for retinitis pigmentosa | ||
Medical condition: PDE6A-linked retinitis pigmentosa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000730-19 | Sponsor Protocol Number: DC2019ROCKIES1 | Start Date*: 2020-03-05 |
Sponsor Name:Amsterdam Univeristy Medical Center - Vu Univeristy Medical Center | ||
Full Title: A phase 4, monocenter, prospective, randomized, placebo-controlled, double-blind, cross-over mechanistic intervention trial to assess effect of 4-week Ertugliflozin (SGLT-2 inhibitor) therapy on re... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021722-35 | Sponsor Protocol Number: HYKP1015 | Start Date*: 2010-10-08 | |||||||||||
Sponsor Name:Moorfields Eye Hospital | |||||||||||||
Full Title: Diabetic macula oedema: A prospective randomised study comparing the detailed functional and anatomical changes of repeated pan anti-VEGF therapy with ranibizumab versus conventional macular laser ... | |||||||||||||
Medical condition: Diabetic macular oedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002373-95 | Sponsor Protocol Number: 270682 | Start Date*: 2021-01-07 |
Sponsor Name:Haukeland University Hospital | ||
Full Title: Study of Mesenchymal Autologous stem cells as Regenerative Treatment for Multiple Sclerosis | ||
Medical condition: Multiple sclerosis (MS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003253-36 | Sponsor Protocol Number: LBS-008-CT03 | Start Date*: Information not available in EudraCT |
Sponsor Name:Belite Bio, Inc | ||
Full Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects | ||
Medical condition: Stargardt Disease | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003631-21 | Sponsor Protocol Number: CLNA043A12203 | Start Date*: 2021-06-28 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, four-arm, canakinumab placebo-controlled, participant, investigator and sponsor-blinded study investigating the safety, tolerability and efficacy of intra-articular canakinumab follow... | |||||||||||||
Medical condition: osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) EE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003517-33 | Sponsor Protocol Number: CRFB002A2302 | Start Date*: 2005-11-11 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal... | ||
Medical condition: Male and female patients ≥50 years of age with either with predominantly classic, minimally classic, or occult lesions with no classic component, all with primary or recurrent subfoveal CNV seconda... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) AT (Completed) DE (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) IT (Completed) BE (Completed) FI (Completed) SE (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002696-10 | Sponsor Protocol Number: CCPK850X2202 | Start Date*: 2018-05-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa c... | |||||||||||||
Medical condition: retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004981-16 | Sponsor Protocol Number: 1991-201-008 | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:Editas Medicine, Inc. | |||||||||||||
Full Title: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Cen... | |||||||||||||
Medical condition: Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in I... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002628-34 | Sponsor Protocol Number: thorp8617-1 | Start Date*: 2012-08-29 | |||||||||||
Sponsor Name:Thor Petersen | |||||||||||||
Full Title: Optic neuritis and early treatment with methylprednisolone. | |||||||||||||
Medical condition: Optic neuritis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
